GYRE vs MYI Comparison

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is an investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes, as is consistent with its investment policies and prudent investment management. The fund invests a majority of its assets in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). Under normal market conditions, the fund invests mainly in long-term municipal obligations that are investment-grade quality or are considered by the adviser to be of comparable quality at the time of investment. It can also invest directly in such securities or synthetically through the use of derivatives.